| Ytd | -37.70% | |
| 1y | -64.01% |
| Open | 0.51 | Prev Close | 0.52 | Low | 0.51 | High | 0.58 | Mkt Cap | 54.03M |
| Vol | 616.14K | Avg Vol | 979.97K | EPS | -1.90 | P/E | N/A | Forward P/E | 33.00 |
| Beta | 0.89 | Short Ratio | 8.84 | Inst. Own | 54.91% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-06 | 50-d Avg | 0.60 | 200-d Avg | 0.85 | 1yr Est | 6.22 |
DCGO News
DocGo Inc. (DCGO) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
DocGo Inc. (Nasdaq: DCGO) (âDocGoâ or the âCompanyâ), a leading provider of technology-enabl
In conjunction with this launch, PTI Health has expanded its relationship with a major national clin
NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider
DocGo NASDAQ: DCGO Chief Executive Officer Lee Bienstock outlined the company's transition away from
DocGo Inc. (DCGO) Q1 2026 Earnings Call Transcript
DocGo NASDAQ: DCGO reported first-quarter revenue of $75.6 million and an adjusted EBITDA loss of $1
DocGo Inc. (DCGO) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estim
DocGo (NASDAQ:DCGO) raises FY2026 sales outlook from $290.000 million-$310.000 million to $300.000 m
DocGo (NASDAQ:DCGO) reported quarterly losses of $(0.15) per share which missed the analyst consensu
NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider
NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo”), a leading provider of technology-ena
NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider
Shares of DocGo Inc. (NASDAQ: DCGO - Get Free Report) have earned an average rating of "Hold" from t
DocGo (NASDAQ: DCGO - Get Free Report) and CochLear (OTCMKTS:CHEOY - Get Free Report) are both medic
Canaccord Genuity analyst Richard Close maintains DocGo (NASDAQ:DCGO) with a Hold and lowers the
NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider
Stifel analyst David Grossman maintains DocGo (NASDAQ:DCGO) with a Buy and lowers the price targe
Cantor Fitzgerald analyst Sarah James reiterates DocGo (NASDAQ:DCGO) with a Overweight and mainta
DocGo Inc. (DCGO) Q4 2025 Earnings Call Transcript
DocGo Inc. (DCGO) came out with a quarterly loss of $0.53 per share versus the Zacks Consensus Estim
DocGo (NASDAQ:DCGO) reported quarterly losses of $(1.37) per share which missed the analyst consensu
NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider
Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or ob
DocGo (NASDAQ: DCGO) executives and TD Cowen healthcare facilities and services analyst Charles Rhye
NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider
NEW YORK--(BUSINESS WIRE)--DocGo Inc. (Nasdaq: DCGO) (“DocGo”), a leading provider of technology-ena
SteadyMD to Grow Clinical Staff by Up To 50% to Support Customer Base That Includes Multiple Fortune
DocGo (NASDAQ:DCGO) reported quarterly losses of $(0.11) per share which beat the analyst consensus
DocGo (NASDAQ:DCGO) narrows FY2025 sales outlook from $300.000 million-$330.000 million to $315.000
DocGo Inc. (Nasdaq: DCGO) ("DocGo" or the "Company"), a leading provider of technolo
Strategic Acquisition Combines DocGo's Last Mile Healthcare Delivery Capabilities With SteadyMD&
Canaccord Genuity analyst Richard Close maintains DocGo (NASDAQ:DCGO) with a Hold and raises the
DocGo (NASDAQ:DCGO) affirms FY2025 sales outlook from $300.000 million-$330.000 million to $300.000
DocGo (NASDAQ:DCGO) reported quarterly losses of $(0.11) per share which missed the analyst consensu
Canaccord Genuity analyst Richard Close downgrades DocGo (NASDAQ:DCGO) from Buy to Hold and lower
Needham analyst Ryan MacDonald maintains DocGo (NASDAQ:DCGO) with a Buy and lowers the price targ